73 results
424B3
ZVRA
Zevra Therapeutics Inc
10 Oct 23
Prospectus supplement
5:07pm
on management’s assessment of internal controls over financial reporting. Investors may lose confidence in the reliability of Acer’s financial statements, which … assessment of the Acer Board that the terms of the Merger Agreement, including the parties’ representations, warranties and covenants
S-4/A
ZVRA
Zevra Therapeutics Inc
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
registered public accounting firm’s attestation on management’s assessment of internal controls over financial reporting. Investors may lose confidence … on page 140 in this proxy statement/prospectus; and
A general assessment of the Acer Board that the terms of the Merger Agreement, including the parties
S-4
euaf9lf8vhsrfv 2it
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
425
le3ipbzm97a
31 Aug 23
Business combination disclosure
8:03am
8-K
EX-2.1
rkfx0t2aki6
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-10.3
zg3e6
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-10.2
v9kq2p zxln7b972d
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-10.1
velqm l1etayczqq
31 May 22
Entry into a Material Definitive Agreement
9:13pm
8-K
EX-99.2
bj8y2dfkvzjke
16 May 22
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
8:40am
424B3
4nmv6vr9v4usyql mjf
19 Jan 22
Prospectus supplement
9:43pm